Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Both Ford and Pfizer have very attractive dividend yields.

Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Shares of Pfizer Inc. PFE advanced 1.03% to $25.43 Tuesday, on what proved to be an all-around favorable trading session for ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

While UBS is positive on Pfizer’s recent Metsera obesity deal, analysts said more business development or acquisitions will be needed. They flagged upcoming Phase II obesity data in early 2026 as a ...